Axitinib/axitinib are the first-line treatment options

Axitinib/Axitinib is an oral small molecule targeted drug mainly used to treat advanced renal cell carcinoma (RCC). Based on current clinical studies and treatment guidelines, axitinib is typically classified as a second-line treatment option, particularly after patients develop resistance to other systemic treatments, such as immunotherapy or other targeted therapies. However, studies in recent years have also explored its use in first-line treatment.

In first-line treatment, axitinib can be combined with immune checkpoint inhibitors, such as avelumab or pembrolizumab, to improve efficacy. This combination has been shown to improve progression-free survival and overall survival in certain patient populations. Therefore, axitinib's status in first-line treatment is gradually being recognized, providing a new treatment option for more patients with advanced renal cell carcinoma.

As a second-line treatment, the indications of axitinib are more clear. Axitinib can be an effective follow-up treatment option if the disease progresses after patients have previously received other treatments, such as classic targeted therapies such as sorafenib or sunitinib. Its mechanism of action is mainly by inhibiting vascular endothelial growth factor (VEGF) receptors, thereby reducing the blood supply of tumors and inhibiting tumor growth and metastasis.

Clinical trials have shown that axitinib has significant efficacy in patients with advanced renal cell carcinoma, and its side effects are relatively controllable. Common adverse reactions include hypertension, fatigue, diarrhea, and stomatitis, which can usually be alleviated with appropriate management and supportive care. When doctors use axitinib, they will individually adjust the dosage according to the patient's specific conditions to achieve the best therapeutic effect.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9##